Application of Akaike information criterion to evaluate warfarin dosing algorithm.

INTRODUCTION Several factors responsible for inter-individual differences in response to warfarin have been confirmed; however, unidentified factors appear to remain. The purpose of this study was to examine a simple method to evaluate whether optional variables are appropriate as factors to improve dosing algorithms. MATERIALS AND METHODS All patients were Japanese. Genotyping of selected genes was conducted, and other information was obtained from medical record. Dosing algorithms were constructed by multivariate linear regression analyses and were evaluated by the Akaike Information Criterion (AIC). RESULTS AND CONCLUSIONS Multivariate analysis showed that white blood-cell count (WBC), concomitant use of allopurinol, and CYP4F2 genotype are apparently involved in warfarin dose variation, in addition to well-known factors, such as age and VKORC1 genotype. We evaluated the adequacy of these variables as factors to improve the dosing algorithm using the AIC. Addition of WBC, allopurinol administration and CYP4F2 genotype to the basal algorithm resulted in decreased AIC, suggesting that these factor candidates may contribute to improving the prediction of warfarin maintenance dose. This study is the first to evaluate the warfarin dosing algorithm by AIC. To further improve the dosing algorithm, AIC may be a simple and useful tool to evaluate both the model itself and factors to be incorporated into the algorithm.

[1]  Zhenya Shen,et al.  Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients , 2007, European Journal of Clinical Pharmacology.

[2]  M. Rieder,et al.  An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients , 2008, Thrombosis and Haemostasis.

[3]  Igor V. Tetko,et al.  Neural network studies, 1. Comparison of overfitting and overtraining , 1995, J. Chem. Inf. Comput. Sci..

[4]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[5]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[6]  L. Becquemont Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice , 2008, European Journal of Clinical Pharmacology.

[7]  R. Todeschini,et al.  Detecting bad regression models: multicriteria fitness functions in regression analysis , 2004 .

[8]  Nicole Soranzo,et al.  A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose , 2009, PLoS genetics.

[9]  M. Margaglione,et al.  Genetic Modulation of Oral Anticoagulation with Warfarin , 2000, Thrombosis and Haemostasis.

[10]  Howard L McLeod,et al.  Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin , 2003, Thrombosis and Haemostasis.

[11]  M. Margaglione,et al.  Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors. , 2008, Blood reviews.

[12]  N. Bodor,et al.  Neural network studies: Part 3. Prediction of partition coefficients , 1994 .

[13]  N. Ariyoshi,et al.  Development of Simple, Simultaneous Genotyping Method Applicable to Individualized Warfarin Therapy , 2009 .

[14]  J. Feely,et al.  Allopurinol Influences Aminophenazone Elimination , 1990, Clinical pharmacokinetics.

[15]  Kaori Matsumoto,et al.  Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions. , 2005, International journal of pharmaceutics.

[16]  C. Thorn,et al.  Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans , 2008, Clinical pharmacology and therapeutics.

[17]  H. Halkin,et al.  A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. , 2007, Blood.

[18]  G. Kitagawa,et al.  Generalised information criteria in model selection , 1996 .

[19]  M. Charng,et al.  A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. , 2005, Human molecular genetics.

[20]  M. Rawlins,et al.  Influence of allopurinol on drug metabolism in man , 1973, British journal of pharmacology.

[21]  H. Arnesen,et al.  Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction , 2008, Thrombosis journal.

[22]  Howard L McLeod,et al.  Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype , 2005, Thrombosis and Haemostasis.

[23]  M. Burns Management of Narrow Therapeutic Index Drugs , 1999, Journal of Thrombosis and Thrombolysis.

[24]  Y. Kokubo,et al.  Polymorphisms in Vitamin K—Dependent γ-Carboxylation—Related Genes Influence Interindividual Variability in Plasma Protein C and Protein s Activities in the General Population , 2006, International journal of hematology.

[25]  S. Hunt,et al.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.

[26]  Yusuke Nakamura,et al.  High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population , 2007, Journal of Human Genetics.

[27]  M. Ritchie,et al.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.

[28]  Panos Deloukas,et al.  The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.

[29]  Selecting a Measurement Model for the Analysis of the National Institutes of Health Stroke Scale , 2009, The International journal of neuroscience.

[30]  S. Looney,et al.  Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms , 2002, Journal of Thrombosis and Thrombolysis.

[31]  T. Wienker,et al.  VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation , 2005, Thrombosis and Haemostasis.

[32]  Gregg D. Wilensky,et al.  Neural Network Studies , 1993 .

[33]  T. Miyata,et al.  Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. , 2007, Thrombosis research.

[34]  B. Horne,et al.  Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.

[35]  C. Mestres,et al.  Racial and ethnic differences in warfarin response. , 2004, The Journal of heart valve disease.

[36]  H. Halkin,et al.  Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin , 2006, Thrombosis and Haemostasis.

[37]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[38]  G. Lip,et al.  Novel oral anticoagulants , 2009, International journal of clinical practice.

[39]  T. Ishizaki,et al.  Genetic analysis of CYP2C9 polymorphism in a Japanese population. , 1997, Pharmacogenetics.

[40]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[41]  M. Rieder,et al.  γ‐Glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose , 2007, Journal of thrombosis and haemostasis : JTH.

[42]  E. Hylek,et al.  Genetic Testing for Warfarin Dosing? Not Yet Ready for Prime Time , 2008, Pharmacotherapy.

[43]  H. Akaike A new look at the statistical model identification , 1974 .

[44]  Y. Turpaz,et al.  CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.

[45]  B. Goh,et al.  Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population , 2006, Clinical pharmacology and therapeutics.